Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dice Therapeutics Inc (NQ: DICE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 47.45 (10)
Ask (Size) 47.81 (2)
Prev. Close 47.55
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
Via Investor Brand Network
Exposures Product Safety
Why These 3 Large Caps Are Bucking the August Slump
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
Exposures Fossil Fuels Interest Rates US Equities

Performance

More News

Read More
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Via Benzinga
Analyst Expectations for DICE Therapeutics's Future
Via Benzinga
Health Care Company Eli Lilly Announces Acquisition of DICE Therapeutics
Via Benzinga
Top 5 Health Care Stocks That May Crash In Q3
Via Benzinga
Eli Lilly To Report Q2 Earnings: What's In The Cards?
Via Talk Markets
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
Via Benzinga
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
Why Shares of Ventyx Biosciences Rose Monday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Via Benzinga
Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review
Via Investor's Business Daily
Why Dice Therapeutics Stock Bolted Higher This Week
Via The Motley Fool
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
Via The Motley Fool
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023
Via Benzinga
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
Via MarketBeat
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Via The Motley Fool
Crude Oil Down 2%; Dragonfly Energy Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Dips Over 300 Points; DICE Therapeutics Shares Spike Higher
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
Via Spotlight Growth
Why Shares of Dice Therapeutics Are Skyrocketing Tuesday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.